Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf
Brand Names: Phesgo
Methodology & AI Transparency ⓘ
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 1200 mg/15mL / 600 mg/15mL Injection, Solution and 600 mg/10mL / 600 mg/10mL Injection, Solution and manufactured/labeled by Genentech, Inc.
- 2 Real-world patient consensus: 88% patient "Worth It" rating across 20 anonymous logs for Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (RxNorm RXN-50242245-2941).
- 3 Typical cash cost range: Public pharmacy ledger: $23.89 low cash benchmark vs. $58.53 chain retail average ($0.3800/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf: nausea (7.9%), headache (7.9%), dizziness (5.5%).
Ask our AI Specialists anything about Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 1200 mg/15mL / 600 mg/15mL Injection, Solution and 600 mg/10mL / 600 mg/10mL Injection, Solution and manufactured/labeled by Genentech, Inc. (NDC 50242-245, 50242-260), Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf operates within subcutaneous-route endoglycosidase treatment algorithms requiring prescription authorization.
Delivered via 1200 mg/15mL / 600 mg/15mL Injection, Solution and 600 mg/10mL / 600 mg/10mL Injection, Solution (subcutaneous-route; NDC 50242-245, 50242-260), Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf mediates endoglycosidase physiological effects manufactured/labeled by Genentech, Inc. with dose-dependent receptor occupancy and systemic clearance.
Pharmacokinetic profiling of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf demonstrates an elimination half-life of Biphasic clearance with 11–17 hr terminal t½ under Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf maintenance with Complete (~100%) parenteral systemic delivery for Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (1200 mg/15mL / 600 mg/15mL Injection, Solution) systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (pertuzumab, trastuzumab, and hyaluronidase-zzxf), reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after pertuzumab, trastuzumab, and hyaluronidase-zzxf administration.
Titration schedules for Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (1200 mg/15mL / 600 mg/15mL Injection, Solution → 600 mg/10mL / 600 mg/10mL Injection, Solution) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to pertuzumab, trastuzumab, and hyaluronidase-zzxf or pertuzumab, trastuzumab, and hyaluronidase-zzxf excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 pertuzumab, trastuzumab, and hyaluronidase-zzxf spl; real-world patient logs highlight nausea (7.9% of reports), headache (7.9% of reports), fatigue (5.6% of reports) alongside a 88.00% Worth-It consensus.
Avoid overlapping endoglycosidase prescriptions alongside Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf SPL
Logged Side-Effect Incidence (20 Reports)
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and: What a 4,804-Participant Study Found Pertuzumab improved IDFS in all subgroups, with the greatest improvement in HER2 FISH-low/estrogen receptor-positive tumors. Journal of the National Cancer Institute • 2026-08-01 • Phase III Randomized Trial | N = 4,804 | 96/100 | PMID 41934626 ↗ |
| New Insights on TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative,: What a 412-Participant Study Found TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer. ESMO open • 2026-01-15 • Phase III Randomized Trial | N = 412 | 93/100 | PMID 41401771 ↗ |
| New Insights on Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously: What a 243-Participant Study Found The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Breast cancer research and treatment • 2023-02-15 • Phase III Randomized Trial | N = 243 | 88/100 | PMID 36463547 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and A planned total 330 patients will be enrolled from 45 institutions over 6.5 years. Japanese journal of clinical oncology • 2021-08-30 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34215870 ↗ |
| Can This Approach Help? Inside the Latest Research on Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, The incidence of treatment-related side effects was similar between groups except for diarrhea. Cancer science • 2022-09-15 • Phase III Randomized Trial | N = 110 | 82/100 | PMID 35754298 ↗ |
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3800/unit (~$11.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $58.53 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $23.89 / mo | View logs ↓ |
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf RxNorm Concept ID | RXN-50242245-2941 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $58.53 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $23.89 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf integrating DailyMed SPL (2026-07-01), CMS NADAC ($0.3800/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf community threads and patient logs by age, biological sex, dosage, and treatment duration.